CA-4948 是白介素 1 受体相关激酶 4 (IRAK4) 的选择性抑制剂，口服有活性，摘自专利文献 WO2015104688 A1 (例 1)。它可用于研究癌症以及炎症疾病。

CA-4948 (previously AU-4948) is a selective and potent IRAK4 kinase inhibitor with in vivo activity in a TLR4-induced cytokine release model.

CA-4948 was previously shown to exhibit dose-dependent efficacy in ABC-DLBCL MYD88-L265P xenograft tumor models using cell lines OCI-LY3 and OCI-LY10[1].

CA-4948 has antitumor activity in ABC-type diffuse large B cell lymphoma patient-derived xenograft (PDX) mouse models[2].

1801343-74-7

C21H19N7O3

417.429

CA-4948

DMSO:13.89 mg/mL (33.28 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years